Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com
Stock analysts at StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Get Free Report) in a note issued to investors on Monday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock. Separately, HC Wainwright reaffirmed a “neutral” rating and set a $5.00 price target on shares of Minerva Neurosciences in a […]
12 Mar 05:46 · The Markets Daily